Wessex Secure Data Environment - Home Part of the NHS Research Secure Data Environment Network NHS

Wessex Genomics Insights

Lay Description

This project aims to deepen our scientific understanding of diseases and their mechanisms. By studying genetic information alongside detailed clinical data e.g. symptoms and outcomes, researchers hope to discover new insights into the causes of diseases (“mechanistic insight”). A primary goal is to improve “diagnostic uplift,” which means finding accurate molecular causal diagnoses for patients where their symptom are likely to have an underlying genetics cause – but this is not currently known. This can be the case for patient with rare diseases and inherited or sporadic cancers. Understanding the molecular genetic cause of disease or cancer helps in the development and personalised prescribing of medicines tailored to target the cause of ill health at an individual level. Additionally, the project intends to explore “pharmacogenomics,” examining how genetic variations influence how patients respond to medications, including hypo or hyper response and/or potential adverse reactions.

The study will focus on patients from University Hospital Southampton (UHS) who have been referred for genomic testing within the NHS. This referral will have been made by the individual’s clinical team because of high suspicion of a genetic cause or driver. Researchers will securely extract genomic data (DNA information) and link it with “longitudinal clinical outcome data” (detailed medical records tracked over time) within the Wessex SDE.

The team will use statistical and mathematical modelling tools, test and validate approaches using artificial intelligence (AI) including decision support software, to analyse this combined data. They plan to use standardised medical terms (e.g. ICD10 codes, SNOMED CT, Human Phenotype Ontology (HPO)) to describe patients’ symptoms in a standardised format aligned with FAIR data principles. Using the SDE will enable granular clinical data to be sourced from across the range of clinical specialities and better connect a patient’s genetic makeup (“genotype”) with their clinical manifestations and symptoms (“phenotype”). This can be particularly important for patients with syndromes requiring care from across many clinical specialities e.g. a child with neurodevelopmental delay who has congenital heart defects and deafness may have important clinical details recorded within neurology, cardiology and audiology. Gathering the list of symptoms from across specialities in a standardised form and integrating with genomic data, is likely to increase the chance a causal diagnosis can be found. Current standard of care means that patients are often referred for genetic testing by one speciality and details provided in the test referral are often limited to that time point and that speciality. This limits the interpretive value of expensive genetic data that is generated for that patient and results in a negative report.

Public Benefit Statement

This project unlocks the potential of high-value genomic data that has already been generated but is currently underutilised. By combining this genetic information with up-to-date and comprehensive hospital records, the study maximises the benefit for patients.

The value lies in potentially identifying missed diagnoses for patients with rare diseases or cancer across a wide range of medical specialties, from neurology (brain and nerves) to ophthalmology (eyes). It may also help identify patients who could benefit from participating in clinical trials for new treatments. Furthermore, the project creates opportunities for training and education for healthcare professionals and researchers, enhancing the overall capability of the genomic medicine service.

Further information

Health Category (HCRS Category)
Generic health relevance
Project Status
Live - Contracts signed 
Research Organisation
University Hospital Southampton
Contracting organisation
Unique ID
SDE_WXS_PROJ_128
Date of counter-signed DAA/DSA
January 30, 2026
Period of DAA
to 31/12/2029